BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2
Annette B. Vogel(BioNTech (United States)), Joshua A. Lees(Pfizer (United States)), Stefan Schille(BioNTech (Germany)), Stephanie Fesser(BioNTech (Germany)), Sarah C. Dany(BioNTech (Germany)), Yvonne Feuchter(BioNTech (Germany)), Ye Che(Pfizer (United States)), Rani S. Sellers(Pfizer (United States)), Matthew C. Griffor(Pfizer (United States)), Kena A. Swanson(Pfizer (United States)), Shannan Hall-Ursone(Texas Biomedical Research Institute), Stephanie Hein(BioNTech (Germany)), Alptekin Güler(BioNTech (Germany)), Stephanie Erbar(BioNTech (Germany)), Ramón de la Caridad Güimil Garcia(BioNTech (Germany)), Journey Cole(Texas Biomedical Research Institute), Julia Schlereth(BioNTech (Germany)), Kristin Tompkins(University of Rochester), Jane Fontenot, Ayuko Ota‐Setlik(Pfizer (United States)), Thomas Hiller(BioNTech (Germany)), Stefanie A. Krumm(BioNTech (Germany)), Jakob Loschko(Pfizer (United States)), Bianca Sänger(BioNTech (Germany)), Isis Kanevsky(Pfizer (United States)), Seungil Han(Pfizer (United States)), Petra Adams‐Quack(BioNTech (Germany)), Mathias Vormehr(BioNTech (Germany)), Kerstin C. Walzer(BioNTech (Germany)), Shambhunath Choudhary(Pfizer (United States)), Arianne Plaschke(BioNTech (Germany)), Matthew R. Gutman(Virginia Cancer Specialists), Christoph Kröner(BioNTech (Germany)), Ferdia Bates(BioNTech (Germany)), Thomas Ziegenhals(BioNTech (Germany)), David Eisel(BioNTech (Germany)), Fulvia Vascotto(Johannes Gutenberg University Mainz), Lena M. Kranz(BioNTech (Germany)), Alexander Muik(BioNTech (Germany)), Kathleen M. Brasky(Texas Biomedical Research Institute), Mohan S. Maddur(Pfizer (United States)), Andreas A. H. Su(BioNTech (Germany)), Ann-Kathrin Wallisch(BioNTech (Germany)), Bernadette Jesionek(BioNTech (Germany)), Hanna Junginger(BioNTech (Germany)), Bonny Gaby Lui(BioNTech (Germany)), André P. Heinen(Johannes Gutenberg University Mainz), Olga González(Texas Biomedical Research Institute), Diana Schneider(BioNTech (Germany)), Leyla Fischer(BioNTech (Germany))
Cited by 22
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
|Nature|2020|1.6k
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
|New England Journal of Medicine|2021|937